Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Authors: Schwedt et al.

Neurol Ther. 2023 Nov 10. Online ahead of print.

PMID: 37948006 | DOI: 10.1007/s40120-023-00562-w

Sign Up For An MSC Newsletter

Sign up for:

Register to Watch the MSC Emerging Science Contest!

The MSC Emerging Science Contest for Young Investigators will take place on Wednesday, December 13, 2023, from 8-10 PM Eastern (US) time. We welcome those who wish to watch the event as an attendee. Register here to attend, and learn more about the contest here.

Discussion

Leave a Comment

You must be logged in to post a comment.

Search

  • Content Types

  • Paper Categories

  • Paper Dates

Paper Categories

By Date